Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Patient selection for transcatheter mitral valve implantation: why is it so hard to find patients?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The role of the Heart Team in the planning of aortic valve replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Will the Evolut Low Risk trial change my practice?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Durability of transcatheter bioprosthetic aortic valves: the story so far

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The EuroIntervention health check 2019

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Transcatheter Aortic Valve Replacement: Role of Multimodality Imaging in Common and Complex Clinical Scenarios

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Simplification of Transcatheter Aortic Valve Replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The role of the Heart Team in the planning of aortic valve replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Will the Evolut Low Risk trial change my practice?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Both transcatheter mitral valve repair and replacement have been introduced in patients with severe mitral regurgitation (MR). However, while transcatheter mitral valve repair is rapidly evolving, transcatheter mitral valve implantation (TMVI) has had a slow development path. One of the main reasons for this is the challenge to find good candidates for this therapy. Although scarce data exist for patient inclusion and/or exclusion criteria and patient screening, the current rejection rate for TMVI is reported to be around 60%. The rejection could be due to: 1) the restriction of the technique to patients at high and extreme surgical risk, as well as the exclusion of patients in whom intervention will be futile, 2) the complexity of the procedure and the anatomical constraints which are high in patients with native valve disease and in those with severe annular calcification, and 3) low procedural safety with left ventricular outflow tract obstruction as the most feared complication. In the future, new transcatheter heart valve platforms and designs are expected to be available which will reduce the periprocedural complications. Furthermore, evaluation of the mitral valve anatomy before and during the procedure may be more accurate, and more evidence on the best clinical practice is expected, including a comparison of TMVI with transcatheter mitral valve repair and surgical intervention, as well as the long-term follow-up. This will facilitate determining the subset of patients who may potentially benefit from this technology.

OriginalsprogEngelsk
TidsskriftEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Vol/bind14
Udgave nummerAB
Sider (fra-til)AB83-AB90
ISSN1774-024X
DOI
StatusUdgivet - 31 aug. 2018

ID: 56523990